CRISPR Therapeutics AG
CRSP · Healthcare
$56.82
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?
Ultragenyx (RARE) reported Q2 2026 earnings that beat expectations with a narrower loss of $0.90 per share versus consensus of $1.27, and revenues of $214 million surged 28.1% year-over-year, marking the company's highest quarterly revenues. However, despite the strong results, estimate revisions have trended downward over the past month, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns in the coming months.
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
CRISPR Therapeutics shares have gained 7.1% since its Q2 2026 earnings report, outperforming the S&P 500. The company beat earnings estimates with a narrower loss of $0.94 per share versus $1.10 expected, and revenues of $10.2 million exceeded the $7 million consensus. Vertex's Casgevy sales reached $76 million with 151% year-over-year growth. CRISPR has controlled costs across R&D, G&A, and collaboration expenses. Analysts have revised estimates upward by 10.46%, though the stock maintains a Zacks Rank #3 (Hold) with an overall VGM Score of F.
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
Vertex Pharmaceuticals strengthens its dominant position in the cystic fibrosis market after competitor Sionna Therapeutics failed a clinical trial for its CF drug candidate. With continued CF portfolio improvements, patent exclusivity until the late 2030s, and promising newer medicines like Casgevy for rare blood diseases and Journavx for pain management, Wall Street remains bullish on Vertex's growth prospects.